Business Description
vTv Therapeutics is a North Carolina-based drug development company working to bring new oral treatments to patients with diabetes and other long-term conditions. Its most advanced program, cadisegliatin (TTP399), is currently in a Phase III trial for type 1 diabetes and works by targeting a specific protein in the liver to help regulate blood sugar. The company also holds a licensing deal with Newsoara Biopharma to advance a separate class of compounds, while continuing to explore additional drug candidates across a range of chronic diseases.
